Ezponda Ana, De La Huebra Ignacio González, Calvo Marta, Idoate Miguel Ángel, Vivas Isabel
Department of Radiology, Clínica Universidad de Navarra, Pamplona 31008, Spain.
Department of Pathology, Clínica Universidad de Navarra, Pamplona 31008, Spain.
Oncol Lett. 2018 Sep;16(3):4043-4048. doi: 10.3892/ol.2018.9114. Epub 2018 Jul 10.
Pazopanib is the first multitargeted tyrosine-kinase inhibitor approved for the treatment of patients with advanced non-adipocytic soft tissue sarcoma (STS). It has been demonstrated to improve progression-free survival without impairing health-associated quality of life. However, Pazopanib is associated with several adverse side effects associated with inhibition of the vascular endothelial growth factor receptor. These include hepatotoxicity, as manifested by abnormal liver function tests. To the best of our knowledge, the current study presents the first case of a patient with recurrent STS who developed biopsy proven Pazopanib-induced chronic active hepatitis and whose previous computed tomography examination demonstrated multiple hypervascular liver lesions. These lesions were indistinguishable from metastases and to the best of our knowledge, have not been described previously. These lesions therefore appear to be a novel finding of Pazopanib-induced chronic active hepatitis. It is crucial to be aware of this unusual finding within a clinical setting, to avoid overstaging and early discontinuation of effective treatment.
帕唑帕尼是首个被批准用于治疗晚期非脂肪细胞性软组织肉瘤（STS）患者的多靶点酪氨酸激酶抑制剂。已证明它可改善无进展生存期，且不损害健康相关生活质量。然而，帕唑帕尼与抑制血管内皮生长因子受体相关的多种不良副作用有关。这些副作用包括肝功能检查异常所表现出的肝毒性。据我们所知，本研究首次报道了一例复发性STS患者，经活检证实发生了帕唑帕尼诱导的慢性活动性肝炎，其先前的计算机断层扫描检查显示肝脏有多个高血运病变。这些病变与转移瘤难以区分，据我们所知，此前尚未有过相关描述。因此，这些病变似乎是帕唑帕尼诱导的慢性活动性肝炎的一个新发现。在临床环境中意识到这一不寻常的发现至关重要，以避免过度分期和过早停用有效治疗。
